

Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
GENMARK DIAGNOSTICS, INC.
(Exact name of registrant as specified in its charter)

Delaware 27-2053069
(State or other jurisdiction (I.R.S. Employer
of incorporation or organization) Identification No.)
5964 La Place Court
Carlsbad, California 92008
(Address, including Zip Code, of Principal Executive Offices)

Hany Massarany
Chief Executive Officer and President
GenMark Diagnostics, Inc.
5964 La Place Court
Carlsbad, California 92008
(760) 448-4300

Copy to:

Eric J. Stier, Esq.
Senior Vice President, General Counsel and Secretary
GenMark Diagnostics, Inc.
5964 La Place Court
Carlsbad, California 92008
Telephone: (760) 448-4327
Facsimile: (760) 683-6876

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	“	Accelerated filer	x
Non-accelerated filer	“(Do not check if a smaller reporting company)	Smaller reporting company”	
Emerging growth company	“		

1

CALCULATION OF REGISTRATION FEE

Title of Securities to be Registered	Proposed Maximum Amount to be Registered (1)	Proposed Maximum Offering Price per Share (2)	Aggregate Offering Price (2)	Amount of Registration Fee
Common Stock, par value \$0.0001 per share	1,100,000	\$6.97	\$7,667,000	\$955

Pursuant to Rule 416(c) under the Securities Act of 1933, as amended (the "Securities Act"), this registration statement shall also cover any additional securities that may be necessary to adjust the number of shares reserved for issuance pursuant to the Registrant's Amended and Restated 2013 Employee Stock Purchase Plan (as amended, the "2013 Plan") by reason of any stock split, stock dividend or similar adjustment effected without the Registrant's receipt of consideration that results in an increase in the number outstanding shares of the Registrant's common stock.

Estimated solely for the purpose of computing the registration fee pursuant to Rule 457 under the Securities Act (2) and based on the average of the high and low prices per share of the Registrant's common stock on May 29, 2018, as reported on the NASDAQ Global Market.

REGISTRATION OF ADDITIONAL SHARES PURSUANT TO GENERAL INSTRUCTION E

Pursuant to General Instruction E to Form S-8, the Registrant is filing this Registration Statement on Form S-8 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "Commission") to register 1,100,000 additional shares of the Company's common stock for issuance under the GenMark Diagnostics, Inc. Amended and Restated 2013 Employee Stock Purchase Plan (the "2013 Plan"). This Registration Statement hereby incorporates by reference the contents of the Registrant's registration statement on Form S-8 filed with the Commission on June 14, 2013 (Registration No. 333-189348).

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 8. Exhibits.

Exhibit No.	Description
4.1(1)	<u>Certificate of Incorporation.</u>
4.2(2)	<u>Amended and Restated By-Laws.</u>
5.1	<u>Opinion of DLA Piper LLP (US).</u>
23.1	<u>Consent of Ernst & Young LLP, Independent Registered Public Accounting Firm.</u>
23.3	<u>Consent of DLA Piper LLP (US) (filed as a part of Exhibit 5.1).</u>
24.1	<u>Power of Attorney (contained on signature page).</u>
99.1(3)	<u>GenMark Diagnostics, Inc. Amended and Restated 2013 Employee Stock Purchase Plan.</u>

(1) Incorporated by reference to Exhibit 3.1 to the Registrant's registration statement on Form S-1 (File No. 333-165562) filed on March 19, 2010.

(2) Incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on 8-K filed on October 31, 2014.

(3) Incorporated by reference to Appendix A to the Registrant's definitive proxy statement on Schedule 14A filed on April 13, 2018.

* * *

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Carlsbad, State of California, on this 30th day of May, 2018.

GenMark Diagnostics, Inc.

By: /s/ Hany Massarany

Name: Hany Massarany

Title: Chief Executive Officer and President

POWER OF ATTORNEY

Each director and/or officer of GenMark Diagnostics, Inc. whose signature appears below constitutes and appoints Hany Massarany as such person's true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in such person's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Commission granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming that said attorney-in-fact and agent or his substitute or substitutes, may lawfully do or cause to be done by virtue of this Power of Attorney.

Pursuant to the requirements of the Securities Act, this registration statement has been signed by the following persons in the capacities and on the date indicated:

Signature	Title	Date
/s/ Hany Massarany Hany Massarany	Chief Executive Officer, President and Director (principal executive officer)	May 30, 2018
/s/ Scott Mendel Scott Mendel	Chief Financial Officer (principal financial and accounting officer)	May 30, 2018
/s/ James Fox, Ph.D. James Fox, Ph.D.	Chairman of the Board	May 30, 2018
/s/ Daryl J. Faulkner Daryl J. Faulkner	Director	May 30, 2018
/s/ Kevin C. O'Boyle Kevin C. O'Boyle	Director	May 30, 2018
/s/ Michael S. Kagnoff Michael S. Kagnoff	Director	May 30, 2018
/s/ Lisa M. Giles Lisa M. Giles	Director	May 30, 2018